Park et al. showed that the gemcitabine-modified aptamer, APTA-12, significantly improved the anti-tumor activity of gemcitabine in nucleolin-overexpressing pancreatic cancer cells [17]. Here, NUCLEOLIN is linked to familial pancreatic carcinoma.